The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts

Science Advances

Volumn 3, Issue 11, 2017, Pages

  Shi, Xiaolei ^a   Tasdogan, Alpaslan ^a   Huang, Fang ^a   Hu, Zeping ^a,c   Morrison, Sean J ^a   DeBerardinis, Ralph J ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; BIOLOGICAL MATERIALS; BIOMOLECULES; DERMATOLOGY; METABOLISM; METABOLITES; METHYLATION; ONCOLOGY; PATHOLOGY; PROTEINS;

BIOLOGICAL FEATURES; ELEVATED LEVEL; HISTONE METHYLTRANSFERASE; MELANOMA XENOGRAFTS; METABOLIC PHENOTYPE; METABOLITE PROFILING; TRIMETHYLATION; TUMOR PROGRESSIONS;

TUMORS;

B RAF KINASE; BRAF PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; GSK126; HISTONE; INDOLE DERIVATIVE; PROTEIN METHYLTRANSFERASE; PYRIDONE DERIVATIVE; SETDB1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOWN REGULATION; DRUG EFFECT; GENETICS; HUMAN; MELANOMA; METABOLISM; METABOLOME; METABOLOMICS; METASTASIS; METHYLATION; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; RNA INTERFERENCE; XENOGRAFT;

ANIMALS; CELL MOVEMENT; DOWN-REGULATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; HISTONES; HUMANS; INDOLES; MELANOMA; METABOLOME; METABOLOMICS; METHYLATION; MICE; MICE, INBRED NOD; NEOPLASM METASTASIS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 85041902112     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.aao5268     Document Type: Article

References (59)

1. C. M. Balch, J. E. Gershenwald, S.-j. Soong, J. F. Thompson, M. B. Atkins, D. R. Byrd, A. C. Buzaid, A. J. Cochran, D. G. Coit, S. Ding, A. M. Eggermont, K. T. Flaherty, P. A. Gimotty, J. M. Kirkwood, K. M. McMasters, M. C. Mihm Jr., D. L. Morton, M. I. Ross, A. J. Sober, V. K. Sondak, Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).
2. L. Serrone, M. Zeuli, F. M. Sega, F. Cognetti, Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J. Exp. Clin. Cancer Res. 19, 21–34 (2000).
3. A. Amin, R. L. White Jr., High-dose interleukin-2: Is it still indicated for melanoma and RCC in an era of targeted therapies? Oncology 27, 680–691 (2013).
4. M. S. Sabel, V. K. Sondak, Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 8, 451–458 (2003).
5. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
6. R. H. I. Andtbacka, H. L. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney, K. A. Delman, L. E. Spitler, I. Puzanov, S. S. Agarwala, M. Milhem, L. Cranmer, B. Curti, K. Lewis, M. Ross, T. Guthrie, G. P. Linette, G. A. Daniels, K. Harrington, M. R. Middleton, W. H. Miller Jr., J. S. Zager, Y. Ye, B. Yao, A. Li, S. Doleman, A. VanderWalde, J. Gansert, R. S. Coffin, Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).
7. V600E melanoma. Sci. Transl. Med. 7, 279ra41 (2015).
8. J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R.-A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol, Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
9. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Jacques Grob, C. Lance Cowey, C. D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P. F. Ferrucci, A. Hill, J. Wagstaff, M. S. Carlino, J. B. Haanen, M. Maio, I. Marquez-Rodas, G. A. McArthur, P. A. Ascierto, G. V. Long, M. K. Callahan, M. A. Postow, K. Grossmann, M. Sznol, B. Dreno, L. Bastholt, A. Yang, L. M. Rollin, C. Horak, F. Stephen Hodi, J. D. Wolchok, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
10. C. Hao, J. Tian, H. Liu, F. Li, H. Niu, B. Zhu, Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Medicine 96, e7325 (2017).
11. R. M. Webster, S. E. Mentzer, The malignant melanoma landscape. Nat. Rev. Drug Discov. 13, 491–492 (2014).
12. A. C. Obenauf, Y. Zou, A. L. Ji, S. Vanharanta, W. Shu, H. Shi, X. Kong, M. C. Bosenberg, T. Wiesner, N. Rosen, R. S. Lo, J. Massagué, Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520, 368–372 (2015).
13. S. Spranger, R. Bao, T. F. Gajewski, Melanoma-intrinsic b-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
14. E. Quintana, E. Piskounova, M. Shackleton, D. Weinberg, U. Eskiocak, D. R. Fullen, T. M. Johnson, S. J. Morrison, Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci. Transl. Med. 4, 159ra149 (2012).
15. R. J. DeBerardinis, N. S. Chandel, Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).
16. F. Vazquez, J.-H. Lim, H. Chim, K. Bhalla, G. Girnun, K. Pierce, C. B. Clish, S. R. Granter, H. R. Widlund, B. M. Spiegelman, P. Puigserver, PGC1a expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23, 287–301 (2013).
17. M. J. Anasagasti, J. J. Martin, L. Mendoza, E. Obrador, J. M. Estrela, R. S. McCuskey, F. Vidal-Vanaclocha, Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 27, 1249–1256 (1998).
18. K. Le Gal, M. X. Ibrahim, C. Wiel, V. I. Sayin, M. K. Akula, C. Karlsson, M. G. Dalin, L. M. Akyürek, P. Lindahl, J. Nilsson, M. O. Bergo, Antioxidants can increase melanoma metastasis in mice. Sci. Transl. Med. 7, 308re8 (2015).
19. Cancer Genome Atlas Network, Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).
20. I. Tirosh, B. Izar, S. M. Prakadan, M. H. Wadsworth II, D. Treacy, J. J. Trombetta, A. Rotem, C. Rodman, C. Lian, G. Murphy, M. Fallahi-Sichani, K. Dutton-Regester, J.-R. Lin, O. Cohen, P. Shah, D. Lu, A. S. Genshaft, T. K. Hughes, C. G. K. Ziegler, S. W. Kazer, A. Gaillard, K. E. Kolb, A.-C. Villani, C. M. Johannessen, A. Y. Andreev, E. M. Van Allen, M. Bertagnolli, P. K. Sorger, R. J. Sullivan, K. T. Flaherty, D. T. Frederick, J. Jané-Valbuena, C. H. Yoon, O. Rozenblatt-Rosen, A. K. Shalek, A. Regev, L. A. Garraway, Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
21. L. Jiang, A. A. Shestov, P. Swain, C. Yang, S. J. Parker, Q. A. Wang, L. S. Terada, N. D. Adams, M. T. McCabe, B. Pietrak, S. Schmidt, C. M. Metallo, B. P. Dranka, B. Schwartz, R. J. DeBerardinis, Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532, 255–258 (2016).
22. Z. T. Schafer, A. R. Grassian, L. Song, Z. Jiang, Z. Gerhart-Hines, H. Y. Irie, S. Gao, P. Puigserver, J. S. Brugge, Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109–113 (2009).
23. E. Piskounova, M. Agathocleous, M. M. Murphy, Z. Hu, S. E. Huddlestun, Z. Zhao, A. M. Leitch, T. M. Johnson, R. J. DeBerardinis, S. J. Morrison, Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186–191 (2015).
24. T. J. Parmenter, M. Kleinschmidt, K. M. Kinross, S. T. Bond, J. Li, M. R. Kaadige, A. Rao, K. E. Sheppard, W. Hugo, G. M. Pupo, R. B. Pearson, S. L. McGee, G. V. Long, R. A. Scolyer, H. Rizos, R. S. Lo, C. Cullinane, D. E. Ayer, A. Ribas, R. W. Johnstone, R. J. Hicks, G. A. McArthur, Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 4, 423–433 (2014).
25. R. Haq, J. Shoag, P. Andreu-Perez, S. Yokoyama, H. Edelman, G. C. Rowe, D. T. Frederick, A. D. Hurley, A. Nellore, A. L. Kung, J. A. Wargo, J. S. Song, D. E. Fisher, Z. Arany, H. R. Widlund, Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell 23, 302–315 (2013).
26. J. Leiper, P. Vallance, Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43, 542–548 (1999).
27. G. Huszar, Tissue-specific biosynthesis of D-N-monomethyllysine and D-N-trimethyllysine in skeletal and cardiac muscle myosin: A model for the cell-free study of post-translational amino acid modifications in proteins. J. Mol. Biol. 94, 311–326 (1975).
28. H. Huang, B. R. Sabari, B. A. Garcia, C. D. Allis, Y. Zhao, SnapShot: Histone modifications. Cell 159, 458–458.e1 (2014).
29. X. Zhang, H. Wen, X. Shi, Lysine methylation: Beyond histones. Acta Biochim. Biophys. Sin. 44, 14–27 (2012).
30. Y. Zhang, D. Reinberg, Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev. 15, 2343–2360 (2001).
31. Y.-T. Chen, F. Zhu, W.-R. Lin, R.-B. Ying, Y.-P. Yang, L.-H. Zeng, The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother. Pharmacol. 77, 757–765 (2016).
32. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).
33. J. Kaplon, L. Zheng, K. Meissl, B. Chaneton, V. A. Selivanov, G. Mackay, S. H. van der Burg, E. M. E. Verdegaal, M. Cascante, T. Shlomi, E. Gottlieb, D. S. Peeper, A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498, 109–112 (2013).
34. S. Xia, R. Lin, L. Jin, L. Zhao, H.-B. Kang, Y. Pan, S. Liu, G. Qian, Z. Qian, E. Konstantakou, B. Zhang, J.-T. Dong, Y. R. Chung, O. Abdel-Wahab, T. Merghoub, L. Zhou, R. R. Kudchadkar, D. H. Lawson, H. J. Khoury, F. R. Khuri, L. H. Boise, S. Lonial, B. H. Lee, B. P. Pollack, J. L. Arbiser, J. Fan, Q.-Y. Lei, J. Chen, Prevention of dietary-fat-fueled ketogenesis attenuates BRAF V600E tumor growth. Cell Metab. 25, 358–373 (2017).
35. A. V. Probst, E. Dunleavy, G. Almouzni, Epigenetic inheritance during the cell cycle. Nat. Rev. Mol. Cell Biol. 10, 192–206 (2009).
36. J. G. Herman, S. B. Baylin, Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042–2054 (2003).
37. M. F. Fraga, E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, K. Petrie, N. G. Iyer, A. Pérez-Rosado, E. Calvo, J. A. Lopez, A. Cano, M. J. Calasanz, D. Colomer, M. Piris, N. Ahn, A. Imhof, C. Caldas, T. Jenuwein, M. Esteller, Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391–400 (2005).
38. M. Esteller, Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286–298 (2007).
39. D. Zingg, J. Debbache, S. M. Schaefer, E. Tuncer, S. C. Frommel, P. Cheng, N. Arenas-Ramirez, J. Haeusel, Y. Zhang, M. Bonalli, M. T. McCabe, C. L. Creasy, M. P. Levesque, O. Boyman, R. Santoro, O. Shakhova, R. Dummer, L. Sommer, The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 6, 6051 (2015).
40. C. J. Ceol, Y. Houvras, J. Jane-Valbuena, S. Bilodeau, D. A. Orlando, V. Battisti, L. Fritsch, W. M. Lin, T. J. Hollmann, F. Ferré, C. Bourque, C. J. Burke, L. Turner, A. Uong, L. A. Johnson, R. Beroukhim, C. H. Mermel, M. Loda, S. Ait-Si-Ali, L. A. Garraway, R. A. Young, L. I. Zon, The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513–517 (2011).
41. A. Kapoor, M. S. Goldberg, L. K. Cumberland, K. Ratnakumar, M. F. Segura, P. O. Emanuel, S. Menendez, C. Vardabasso, G. LeRoy, C. I. Vidal, D. Polsky, I. Osman, B. A. Garcia, E. Hernando, E. Bernstein, The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468, 1105–1109 (2010).
42. I. M. Bachmann, O. J. Halvorsen, K. Collett, I. M. Stefansson, O. Straume, S. A. Haukaas, H. B. Salvesen, A. P. Otte, L. A. Akslen, EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268–273 (2006).
43. F. Mahmoud, B. Shields, I. Makhoul, L. F. Hutchins, S. C. Shalin, A. J. Tackett, Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol. Ther. 17, 579–591 (2016).
44. S. MacGregor, G. W. Montgomery, J. Z. Liu, Z. Z. Zhao, A. K. Henders, M. Stark, H. Schmid, E. A. Holland, D. L. Duffy, M. Zhang, J. N. Painter, D. R. Nyholt, J. A. Maskiell, J. Jetann, M. Ferguson, A. E. Cust, M. A. Jenkins, D. C. Whiteman, H. Olsson, S. Puig, G. Bianchi-Scarrà, J. Hansson, F. Demenais, M. T. Landi, T. Dębniak, R. Mackie, E. Azizi, B. Bressac-de Paillerets, A. M. Goldstein, P. A. Kanetsky, N. A. Gruis, D. E. Elder, J. A. Newton-Bishop, D. T. Bishop, M. M. Iles, P. Helsing, C. I. Amos, Q. Wei, L.-E. Wang, J. E. Lee, A. A. Qureshi, R. F. Kefford, G. G. Giles, B. K. Armstrong, J. F. Aitken, J. Han, J. L. Hopper, J. M. Trent, K. M. Brown, N. G. Martin, G. J. Mann, N. K. Hayward, Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 43, 1114–1118 (2011).
45. i at 2.8 Å resolution. Biochemistry 35, 2586–2596 (1996).
46. P. B. Alexander, J. Wang, S. L. McKnight, Targeted killing of a mammalian cell based upon its specialized metabolic state. Proc. Natl. Acad. Sci. U.S.A. 108, 15828–15833 (2011).
47. S. J. Mentch, M. Mehrmohamadi, L. Huang, X. Liu, D. Gupta, D. Mattocks, P. Gómez Padilla, G. Ables, M. M. Bamman, A. E. Thalacker-Mercer, S. N. Nichenametla, J. W. Locasale, Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 22, 861–873 (2015).
48. J.-P. Etchegaray, R. Mostoslavsky, Interplay between metabolism and epigenetics: A nuclear adaptation to environmental changes. Mol. Cell 62, 695–711 (2016).
49. B. W. Carey, L. W. S. Finley, J. R. Cross, C. D. Allis, C. B. Thompson, Intracellular a-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413–416 (2015).
50. S. Sharma, T. K. Kelly, P. A. Jones, Epigenetics in cancer. Carcinogenesis 31, 27–36 (2010).
51. F. Traina, V. Visconte, P. Elson, A. Tabarroki, A. M. Jankowska, E. Hasrouni, Y. Sugimoto, H. Szpurka, H. Makishima, C. L. O’Keefe, M. A. Sekeres, A. S. Advani, M. Kalaycio, E. A. Copelan, Y. Saunthararajah, S. T. Olalla Saad, J. P. Maciejewski, R. V. Tiu, Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28, 78–87 (2014).
52. J. Kaiser, Epigenetic drugs take on cancer. Science 330, 576–578 (2010).
53. A. C. West, R. W. Johnstone, New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30–39 (2014).
54. K. Yen, J. Travins, F. Wang, M. D. David, E. Artin, K. Straley, A. Padyana, S. Gross, B. DeLaBarre, E. Tobin, Y. Chen, R. Nagaraja, S. Choe, L. Jin, Z. Konteatis, G. Cianchetta, J. O. Saunders, F. G. Salituro, C. Quivoron, P. Opolon, O. Bawa, V. Saada, A. Paci, S. Broutin, O. A. Bernard, S. de Botton, B. S. Marteyn, M. Pilichowska, Y. Xu, C. Fang, F. Jiang, W. Wei, S. Jin, L. Silverman, W. Liu, H. Yang, L. Dang, M. Dorsch, V. Penard-Lacronique, S. A. Biller, S.-S. M. Su, AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 7, 478–493 (2017).
55. E. Quintana, M. Shackleton, H. R. Foster, D. R. Fullen, M. S. Sabel, T. M. Johnson, S. J. Morrison, Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510–523 (2010).
56. A. R. Mullen, Z. Hu, X. Shi, L. Jiang, L. K. Boroughs, Z. Kovacs, R. Boriack, D. Rakheja, L. B. Sullivan, W. M. Linehan, N. S. Chandel, R. J. DeBerardinis, Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep. 7, 1679–1690 (2014).
57. E. J. J. van Velzen, J. A. Westerhuis, J. P. M. van Duynhoven, F. A. van Dorsten, H. C. J. Hoefsloot, D. M. Jacobs, S. Smit, R. Draijer, C. I. Kroner, A. K. Smilde, Multilevel data analysis of a crossover designed human nutritional intervention study. J. Proteome Res. 7, 4483–4491 (2008).
58. C. Yang, B. Ko, C. T. Hensley, L. Jiang, A. T. Wasti, J. Kim, J. Sudderth, M. A. Calvaruso, L. Lumata, M. Mitsche, J. Rutter, M. E. Merritt, R. J. DeBerardinis, Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell 56, 414–424 (2014).
59. M. T. McCabe, H. M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G. S. Van Aller, Y. Liu, A. P. Graves, A. Della Pietra III, E. Diaz, L. V. LaFrance, M. Mellinger, C. Duquenne, X. Tian, R. G. Kruger, C. F. McHugh, M. Brandt, W. H. Miller, D. Dhanak, S. K. Verma, P. J. Tummino, C. L. Creasy, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).